Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

sful transfer of manufacturing activities to Wyeth during 2007. This decrease was partially offset by increased clinical costs related to the company's Phase IIb clinical trial for TRU-015 and increased personnel-related expenses due to increased headcount.

The 12-month increase was primarily due to increased clinical costs related to the company's Phase IIb clinical trial for TRU-015, increased personnel-related expenses due to increased headcount, and increased outside manufacturing costs related to Trubion's TRU-016 product candidate. These increases were partially offset by lower outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007 and lower non-cash stock-based compensation charges.

Net loss for the fourth quarter of 2007 was $4.9 million, or $0.28 per diluted common share, compared with a net loss of $4.8 million, or $0.33 per diluted common share, for the fourth quarter of 2006. For the year ended Dec. 31, 2007, net loss was $23.3 million, or $1.32 per diluted common share, compared with a net loss of $3.9 million, or $0.83 per diluted common share, for the year ended Dec. 31, 2006.

Trubion had $78.5 million in cash, cash equivalents and investments as of Dec. 31, 2007, compared with $105.8 million as of Dec. 31, 2006.

"In 2007 we continued our mission to develop a family of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience, that could offer improved patient experiences," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "We and our partner continued to advance the clinical development of our lead product candidate, TRU-015, for the treatment of rheumatoid arthritis, began clinical evaluation of TRU-015 in non-Hodgkin's lymphoma (NHL) and expect to do the same in systemic lupus erythematosus (SLE) later this year. In 2008, we expect our research and clinical advance
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Pharmos Corporation,(Nasdaq: PARS ) announced today that ... from the Company., Mr. Rubino joined Pharmos ... acquisition and the subsequent integration of Vela,Pharmaceuticals completed ... has been focused on key business development priorities ...
... Synthetech, Inc. (OTC,Bulletin Board: NZYM) has earned ... outstanding accomplishments in environmental, health,safety and security ... by,the Synthetic Organic Chemical Manufacturers Association (SOCMA) ... awards are highly,regarded and demonstrate Synthetech,s level ...
... Dec. 18 January 1, 2008 will mark the,ritualistic day ... The New,Year also brings added pressure to smokers as January ... For those resolving to make 2008 the start of a ... Laser Therapy,provided by Achieve Laser, is quickly becoming a very ...
Cached Biology Technology:Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company 2Synthetech Earns National Recognition for Performance Improvement Program 2Synthetech Earns National Recognition for Performance Improvement Program 3Laser Therapy Gives Smokers Hope for Successful New Year's Resolution 2
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... This release is also available in Chinese ... (September 28, 2010) -- The second law of thermodynamics is ... its implicit existential crunch. The tendency of a closed systems ... removed is a popular, if not depressing, "things fall apart" ...
... MT. ROYAL, NJ (September 28, 2010) "Migraine feels ... face," says author Andrew Levy in his interview on the ... of Our Heads". "It,s a metaphysical crisis." In the ... his personal experience with managing the pain of migraine, how ...
... (Sept. 28, 2010) -- A new book, RNA ... reviews our understanding of two RNA worlds: the primordial RNA ... and biocatalyst; and the contemporary RNA world, in which mRNA, ... operate. "[T]he plasticity of RNA stemming from ...
Cached Biology News:Tiny generators turn waste heat into power 2American Migraine Foundation launches new podcast series 2New book reviews ancient and modern worlds of RNA 2
... SYBR Safe DNA gel stain was developed ... than ethidium bromide for staining DNA in agarose ... only less mutagenic than ethidium bromide but SYBR ... of ethidium bromide. SYBR Safe stain comes as ...
... Service enables scientists who do not have access ... to have their biological samples tested for the ... easy as 1-2-3 Chose the analytes ... from the S&S antibody menu. Send your ...
... I nucleic acid gel stain is an ... bright fluorescence when bound to dsDNA and low ... dsDNA in gels using laser scanners or standard ... has also found uses in capillary electrophoresis, real-time ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Biology Products: